With new therapeutics under FDA review for migraine, Alzheimer’s disease and seizures, and several rare disease gene therapies in development, stocks included in BioWorld’s Neurological Diseases Index are tracking 6.09% ahead for the year.
Ernst and Young’s (EY) annual Pulse of the Industry report released today provided proof of med tech’s strong rebound from the disruption of the pandemic. Research and development investment soared, deal activity hit new highs, venture capital poured $9.1 billion into the sector, IPOs doubled, and more than 9 out of 10 of commercial leaders reported increased revenues.
For the first time since February, the BioWorld Biopharmaceutical Index (BBI) took a sharp plummet with shares falling in the last few weeks for 18 of the 22 stock components.
While 2020 is certainly a hard year to beat, 2021 has so far recorded a respectable amount of biopharma deals and is on track to exceed every other year. The number this year, including licensings, collaborations and joint ventures, is trailing 2020 by only 3%. BioWorld has recorded 1,447 deals valued at $131.75 billion in 2021 vs. 1,488 worth $141.56 billion last year. That puts 2021 about 7% behind 2020 on deal values.
RSS
